Emergent BioSolutions Announces Presentation on Bispecific Protein Therapeutic at 24th Annual EORTC-NCI-AACR Symposium

Emergent BioSolutions Inc.Robert G. Burrows, 301-795-1877Vice President, Investor RelationsorTracey Schmitt, 301-795-1800Vice President, Corporate Communications

announced today that an abstract on its bispecific protein therapeutic targeting prostate cancer has been accepted for presentation at the 24 Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 6-9, 2012 in Dublin, Ireland.

The preclinical results showed Emergent’s SCORPION (multi-specific protein therapeutic) molecules targeting prostate-specific membrane antigen (PSMA) and CD3 redirected T-cell cytotoxicity against PSMA-positive tumor cells and show potential for further investigation as possible therapeutic agents for treating castrate-resistant prostate cancer. T-cell engaging bispecific molecules linking anti-PSMA and anti-CD3 binding domains in the context of novel SCORPION proteins were evaluated both and for function and stability.

Prostate cancer is the most common cancer in men. Although screening, radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early stage prostate cancer, few options exist to treat metastatic, castrate-resistant prostate cancer. Bispecific antibody fragments that can simultaneously engage T cells and tumor cells have been shown to destroy tumor cells by redirecting the cytotoxic function of T cells.

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about us may be found at .

Follow us on twitter: .

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.